You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 115 No. 6, June 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. The Herpetic Eye Disease Study Group


OBJECTIVE: To evaluate the efficacy of oral acyclovir in preventing stromal keratitis or iritis in patients with epithelial keratitis caused by herpes simplex virus (HSV). METHODS: Patients with HSV epithelial keratitis of 1-week or less duration were treated with topical trifluridine and were randomly assigned to receive a 3-week course of oral acyclovir, 400 mg 5 times a day (hereafter referred to as the acyclovir group), or placebo (hereafter referred to as the placebo group). The development of HSV stromal keratitis or iritis was assessed during 12 months of follow-up. RESULTS: Stromal keratitis or iritis developed in 17 (11%) of the 153 patients in the acyclovir group and in 14 (10%) of the 134 patients in the placebo group. Compared with the placebo group, the adjusted rate ratio for the development of stromal keratitis or iritis in the acyclovir group was 1.16 (95% confidence interval, 0.56-2.43). The development of stromal keratitis or iritis was more frequent in patients with a history of HSV stromal keratitis or iritis than in those without such a history (23% vs 9%; P = .01). CONCLUSIONS: For patients with HSV epithelial keratitis treated with topical trifluridine, no apparent benefit of a 3-week course of oral acyclovir in preventing HSV stromal keratitis or iritis was seen during the subsequent year. The 1-year rate of development of stromal keratitis or iritis was lower than previously reported in the literature, except in patients with a history of HSV stromal keratitis or iritis.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin
Halberstadt et al.
Br. J. Ophthalmol. 2002;86:646-652.
ABSTRACT | FULL TEXT  

Can We Prevent Recurrences of Herpes Infections without Antiviral Drugs? The Weisenfeld Lecture
Kaufman
IOVS 2002;43:1325-1329.
FULL TEXT  

Tegument-Specific, Virus-Reactive CD4 T Cells Localize to the Cornea in Herpes Simplex Virus Interstitial Keratitis in Humans
Koelle et al.
J. Virol. 2000;74:10930-10938.
ABSTRACT | FULL TEXT  

Detection of herpes simplex virus type 1, 2 and varicella zoster virus DNA in recipient corneal buttons
van Gelderen et al.
Br. J. Ophthalmol. 2000;84:1238-1243.
ABSTRACT | FULL TEXT  

Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis
Tambasco et al.
Arch Ophthalmol 1999;117:445-449.
ABSTRACT | FULL TEXT  

Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease
Wilhelmus et al.
NEJM 1998;339:300-306.
ABSTRACT | FULL TEXT  

Prevention of Herpes Simplex Keratitis and Iritis
Bachman and Barron
Arch Ophthalmol 1998;116:259-259.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.